ClinicalTrials.gg
CompletedNCT02460159Updated May 16, 2024Results posted

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

A Phase 3 interventional study of EZ 10 mg/Atorva 20 mg FDC and EZ 10 mg/Atorva 10 mg FDC in Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
54th of 97
135 · median 148
Started
2015
with 1 other
Phase 3
50 of 98
1 open now
Registered
73rd of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 54th largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2015, is one of 50 in phase 3, and was the 73rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Atorvastatin up to 20 mg. There is no formal hypothesis for the study.

03

Conditions studied

  • Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese
  • Outpatient with hypercholesterolemia
  • Has familial hypercholesterolemia (FH) diagnosed per genetic testing or meets two or more of the below criteria based on Japan Atherosclerosis Society Guideline 2012 (JAS2012): Hyper low-density lipoprotein (LDL)-cholesterolemia (an untreated LDL-C level of ≥180mg/dL); tendon xanthoma (tendon xanthoma on the backs of the hands, elbows, knees, etc. or achilles tendon hypertrophy) or xanthoma tuberosum; family history of FH or premature coronary arterial disease (within the participant's second degree relatives)
  • Females must be of non- or agree to remain abstinent or use (or partner use) two acceptable methods of from date of signed to the 14 days after the last dose of study drug
  • Agree to maintain a stable diet that is consistent with the JAS 2012 for prevention of atherosclerotic cardiovascular diseases for the duration of the study

Exclusion criteria

Exclusion Criteria

  • Uncontrolled hypertension
  • Type 1 or uncontrolled type 2 diabetes mellitus (treated or untreated)
  • Homozygous familial hypercholesterolemia or has undergone LDL apheresis
  • Had a gastrointestinal tract bypass, or other significant intestinal malabsorption
  • History of cancer within the past 5 years except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer
  • (HIV) positive
  • History of drug/ alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy
  • Consumes more than 25 g of alcohol per day
  • Consumes more than 1L of grapefruit juice per day
  • Currently following an excessive weight reduction diet
  • Engaging in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study
  • or intolerance to ezetimibe or atorvastatin
  • History of myopathy or rhabdomyolysis with ezetimibe or any statin
  • Pregnant or lactating
  • Taking any other drugs and/or has taken any investigational drugs within 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    EZ 10 mg/Atorva 10 mg FDC

    one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.

    Drug: EZ 10 mg/Atorva 10 mg FDC

  • Experimental
    EZ 10 mg/Atorva 20 mg FDC

    one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.

    Drug: EZ 10 mg/Atorva 20 mg FDC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experience 1 or More Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized.

    Time frame: up to 54 Weeks

  2. Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs

    Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.

    Time frame: up to 54 weeks

  3. Percentage of Participants Who Experience 1 or More Gallbladder-related AEs

    Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.

    Time frame: up to 54 weeks

  4. Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs

    Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.

    Time frame: up to 54 weeks

  5. Percentage of Participants Who Experience 1 or More Hepatitis-related AEs

    Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.

    Time frame: up to 54 weeks

  6. Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)

    Participants had ALT and AST levels assessed throughout the 52 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

    Time frame: up to 52 weeks

  7. Percentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULN

    Participants had ALT and AST levels assessed throughout the 52 week treatment period. Participants who had assessments of ALT or AST that were 5x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

    Time frame: up to 52 weeks

  8. Percentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULN

    Participants had ALT and AST levels assessed throughout the 52 week treatment period. Participants who had assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

    Time frame: up to 52 weeks

  9. Percentage of Participants With Potential Hy's Law Condition

    Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations \>3xULN, with serum alkaline phosphatase \<2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.

    Time frame: up to 52 weeks

  10. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN

    Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

    Time frame: up to 52 weeks

  11. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms

    Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

    Time frame: up to 52 weeks

  12. Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms

    Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

    Time frame: up to 52 weeks

07

Results

Posted Jan 11, 2018

Participant flow

Participant flow — Overall Study
MilestoneEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Started11718
Completed11117
Not completed61
Withdrew: Adverse event41
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryPercentage of Participants Who Experience 1 or More Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized.

Time frame:
up to 54 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Adverse Event (AE)
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience 1 or More Adverse Event (AE)82.988.9
PrimaryPercentage of Participants Who Experience 1 or More Gastrointestinal-related AEs

Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.

Time frame:
up to 54 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs
Percentage of participantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs30.811.1
PrimaryPercentage of Participants Who Experience 1 or More Gallbladder-related AEs

Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.

Time frame:
up to 54 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Gallbladder-related AEs
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience 1 or More Gallbladder-related AEs0.00.0
PrimaryPercentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs

Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.

Time frame:
up to 54 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs6.822.2
PrimaryPercentage of Participants Who Experience 1 or More Hepatitis-related AEs

Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.

Time frame:
up to 54 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience 1 or More Hepatitis-related AEs
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience 1 or More Hepatitis-related AEs0.05.6
PrimaryPercentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)

Participants had ALT and AST levels assessed throughout the 52 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)0.90.0
PrimaryPercentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULN

Participants had ALT and AST levels assessed throughout the 52 week treatment period. Participants who had assessments of ALT or AST that were 5x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULN
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULN0.00.0
PrimaryPercentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULN

Participants had ALT and AST levels assessed throughout the 52 week treatment period. Participants who had assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULN
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULN0.00.0
PrimaryPercentage of Participants With Potential Hy's Law Condition

Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations \>3xULN, with serum alkaline phosphatase \<2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Potential Hy's Law Condition
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants With Potential Hy's Law Condition0.00.0
PrimaryPercentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN

Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN0.00.0
PrimaryPercentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms

Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms0.00.0
PrimaryPercentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms

Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.

Time frame:
up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms
Percentage of ParticipantsEZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDC
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms0.00.0

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EZ10/AT100/117 (0%)7/117 (6%)77/117 (65.8%)
EZ10/AT200/18 (0%)2/18 (11.1%)16/18 (88.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventEZ10/AT10EZ10/AT20
Extradural haematomaInjury, poisoning and procedural complications0/1171/18
Subdural haematomaInjury, poisoning and procedural complications0/1171/18
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1171/18
Angina pectorisCardiac disorders1/1170/18
Myocardial ischaemiaCardiac disorders1/1170/18
Colitis ischaemicGastrointestinal disorders1/1170/18
Inguinal herniaGastrointestinal disorders1/1170/18
ContusionInjury, poisoning and procedural complications1/1170/18
Cerebral infarctionNervous system disorders1/1170/18
Progressive supranuclear palsyNervous system disorders1/1170/18
Most frequent other events
Showing 10 of 45
Most frequent other events
EventEZ10/AT10EZ10/AT20
NasopharyngitisInfections and infestations50/1177/18
Type 2 diabetes mellitusMetabolism and nutrition disorders11/1172/18
HypoaesthesiaNervous system disorders0/1172/18
Back painMusculoskeletal and connective tissue disorders9/1171/18
Sudden hearing lossEar and labyrinth disorders0/1171/18
Scintillating scotomaEye disorders0/1171/18
DiarrhoeaGastrointestinal disorders2/1171/18
Oral hyperaesthesiaGastrointestinal disorders0/1171/18
Periodontal diseaseGastrointestinal disorders2/1171/18
Chest discomfortGeneral disorders0/1171/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)EZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDCTotal
Mean57.8 ± 12.661.6 ± 10.958.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)EZ 10 mg/Atorva 10 mg FDCEZ 10 mg/Atorva 20 mg FDCTotal
Female48654
Male691281
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Teramoto T, Yokote K, Nishida C, Tershakovec A, Oshima N, Takase T, Hirano T. A Phase III open-label clinical trial to assess the long-term safety of ezetimibe and atorvastatin combination therapy in Japanese patients with hypercholesterolemia. J Clin Therapeut Med. 2017;33(8):655-670.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Dec 2016, 17 months.

Results were first posted in Jan 2018, 1 year after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Jun 2, 2015
StartActual
Jun 23, 2015
Primary completionActual
Dec 22, 2016
CompletionActual
Dec 22, 2016
Results first posted
Jan 11, 2018
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02460159
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
Jun 23, 2015
Primary completion
Dec 22, 2016
Completion
Dec 22, 2016
Results posted
Jan 11, 2018
Last update
May 16, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Atorvastatin

Start the discussion